Related Experiment Video
Updated: Oct 5, 2025

Cheek Injection Model for Simultaneous Measurement of Pain and Itch-related Behaviors
Published on: September 27, 2019
Low dose naloxone for pruritus in systemic sclerosis: Case series and literature review
Katya Meridor1, Joshua Berookhim, Yair Levy
1Department of Internal Medicine, Meir Medical Center, Israel; affiliated with the Sackler Faculty of Medicine, Tel Aviv University, Tel-Aviv, Israel.
Rationale:
Pruritus is a common symptom in patients with systemic sclerosis and has a tremendous effect on the quality of life. Nevertheless, current therapeutic options are limited. The pathogenesis of pruritus in systemic sclerosis is not completely understood; however, opiate-mediated neurotransmission has been postulated to be involved.
Patient Concerns And Diagnosis:
We describe 4 female patients with systemic sclerosis suffering from severe pruritus, with an average 5D-itch score of 22.75.
Intervention And Outcomes:
Low-dose oral naloxone was initiated, followed by a significant improvement in the level of pruritus, reaching an average 5D-itch score of 7.5, after 6 and 12 months of treatment. None of the patients experienced side effects.
Lessons:
Low-dose naloxone plays an important role in the management of pruritus in systemic sclerosis.
Related Concept Videos
Nephrotic Syndrome II : Assessment and Medical Management
Nephrotic Syndrome I : Introduction
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
Nephrotic Syndrome III : Nursing Management
Analgesia and Pain Management

